CRISPR Therapeutics AG

For the period ended Dec 31, 2025. Filed Feb 12, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 12, 2026

CRSP$45.15-9.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)

	Years Ended December 31,
	2025	2024	2023
Revenue:
Collaboration revenue	$—	$35,000	$370,000
Grant revenue	3,510	2,314	1,206
Total revenue	3,510	37,314	371,206
Operating expenses:
Research and development	284,806	310,236	387,332
Acquired in-process research and development	96,253	—	—
General and administrative	73,542	72,977	76,162
Collaboration expense, net	213,480	120,667	130,250
Total operating expenses	668,081	503,880	593,744
Loss from operations	(664,571)	(466,566)	(222,538)
Other income:
Other income, net	86,606	103,901	71,816
Total other income, net	86,606	103,901	71,816
Net loss before income taxes	(577,965)	(362,665)	(150,722)
Provision for income taxes	(3,634)	(3,587)	(2,888)
Net loss	(581,599)	(366,252)	(153,610)
Foreign currency translation adjustment	95	(21)	73
Unrealized gain (loss) on marketable securities	2,886	(52)	17,487
Comprehensive loss	$(578,618)	$(366,325)	$(136,050)
Net loss per common share — basic	$(6.47)	$(4.34)	$(1.94)
Basic weighted-average common shares outstanding	89,925,109	84,359,126	79,220,930
Net loss per common share — diluted	$(6.47)	$(4.34)	$(1.94)
Diluted weighted-average common shares outstanding	89,925,109	84,359,126	79,220,930

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.